
Childhood TB in Ghana: using immunodiagnostics to improve detection and monitoring of response to anti-TB therapy




https://image.slidesharecdn.com/childtbsgcoregroupmtgmay2014stevegraham-140513190332-phpapp01/95/childhood-tuberculosis-andcommunity-healthcaresteve-graham5814-23-638.jpg?cb=1400007897 Tuberculin-Bacteriology Chest X-ray History Skin Test (1890) (1882)(1896)High negative Indicator of Low Low predictive

Introduction

TB disease is often paucibacillary in children and sputum is difficult to obtain particularly from younger children. Hence diagnosis is often based on clinical signs, symptoms and history of TB contact. This often results in over or under-diagnosis as this has poor specificity. This prospective longitudinal study seeks to provide a more accurate/improved diagnostic algorithm for TB in children utilizing a combination of existing and novel tools including blood-based immunodiagnostic assays.

Key Message: This study seeks to provide a more accurate/improved tool for confirming a clinical diagnosis of childhood TB and reduce cases of over or under-diagnosis



Sensitivity

Lead Author

Gloria Ivy Mensah, PhD



niversity of Ghana

gmensah@noguchi.ug.edu

Collaborating authors

- Kennedy Kwasi Addo, NMIMR, Ghana
- Rudovick Kazwala, SUA, **Tanzania**
- **Tanzania**

○ Joram Buza, NM-AIST,

- Bassirou Bonfoh, CSRS, Cote d' Ivoire
- Dolly Jackson-Sillah, LSTMH-UK
- Toidi Adekambi, Emory **Vaccine Institute, USA**
- Christof Geldmacher, DZIF & LMU, Germany

Acknowledgement

This work is supported through the DELTAS Africa Initiative [Afrique One-ASPIRE /DEL-15-008]. The DELTAS Initiative is an independent scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the Africa's Partnership Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107753/A/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.









Research Questions

- Would the addition of novel and existing blood-based diagnostic tools to existing sputum-dependent microbiological tests lead to a more accurate/improved diagnostic algorithm for TB in children?
- What are the risk factors and etiological agents of Childhood TB in Ghana?

Specific Objectives

infection with

limitations

1. To determine the utility of the QFT and TAM TB assay in addition to the traditional sputum-based methods for accurate diagnosis of TB in Children.

Specificity

- 2. To determine the etiological agents of childhood TB in Ghana and drug resistance profile.
- 3. To monitor response to TB treatment in children using the TAM TB assay, QFT test and serum cytokine levels.
- 4. To determine the cytokine response profile of children with or without TB to MTB specific- antigens.
- 5. To determine the major risk factors for childhood TB in Ghana

Methodology

Study design

☐ Prospective/longitudinal (3 time points)

Eligibility

☐ Children below 15 years of age newly diagnosed with TB or presumptive TB

Study sites

☐ Selected Hospitals in Accra/Ghana

Sample size 100 cases and matched controls

Recruitment strategy

☐ Parental consent and child ascent

- ☐ Demographic details
- ☐ Sample collection (Blood and sputum)
 - ☐ Before or within a week of treatment initiation [T1]
 - ☐ After two months of treatment [T2] ☐ Treatment completion [T3]

Laboratory workflow TAM TB ASSAY Microscopy Culture WBA GeneXpert **IGRA CLASSIFICATION DIAGNOSTIC ALGORITHM** MICROSCOPY CULTURE **GENEXPERT CONFIRMED TB PROBABLE TB EXPOSURE TO TB** All culture-positive isolates will undergo speciation using the Genotype MTBC ® from Hain Life Sciences to determine the

Expected outcome

The provision of a more robust diagnostic algorithm, which will allow clinicians to accurately classify children as being exposed, infected or having active TB. Knowledge of the risk factors for progression to active disease would help early initiation of appropriate prophylaxis or anti-TB treatment when needed.










Genotype MTBC®





etiological agents for childhood TB.